Diamyd Medical AB (publ) (DMYD_B) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Diamyd Medical Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.218 Hello and welcome to BioStock. In today's live broadcast we will be talking about Bookstore 00:00:05.218 -- 00:00:10.805 Communiqué and we will do that together with DMU Medical and VD Ulf Hanedius. 00:00:10.805 -- 00:00:15.812 There is an opportunity to ask questions to Ulf in the open chat, but before we get to 00:00:15.812 -- 00:00:19.858 the question section, we will listen to a short presentation from Ulf. 00:00:19.858 -- 00:00:23.202 And before we do that, of course, we will say welcome to Ulf. 00:00:23.202 -- 00:00:24.203 Hi Ulf. 00:00:24.203 -- 00:00:26.390 Thank you very much. Nice to have you here. 00:00:26.390 -- 00:00:31.497 Very nice to have you here. Before I let you start your presentation, I would 00:00:31.497 -- 00:00:36.744 like to ask two short questions. The first one is, could you 00:00:36.744 -- 00:00:42.248 just summarize the three most important events from this reporting period? 00:00:42.651 -- 00:00:47.057 Three most important. If we think regulatory and on the clinic side, it is most important 00:00:47.057 -- 00:00:49.881 that we are now at the end of the track with patient recruitment. 00:00:49.881 -- 00:00:55.287 In the FAST-3 study, we have been 275 patients So we plan to end the 00:00:55.287 -- 00:01:00.514 screening for new patients this year. We are also preparing for 00:01:00.514 -- 00:01:04.219 the early reading that is expected in March next year. 00:01:04.219 -- 00:01:09.546 So in six months we will have an early reading from the FAST-3 study 00:01:09.546 -- 00:01:12.610 that can lay the groundwork for an accelerated approval in the USA. 00:01:12.610 -- 00:01:18.376 In terms of manufacturing and science, we also have our facility in Umeå 00:01:18.376 -- 00:01:23.701 on track to get GMP certifica...